Table 1 |
|||
|
p42/p44 MAP kinase Activating agents in Prostatic cells |
|||
| Agent |
Cell line |
Cell effect |
Ref |
|
|
|||
| Endogenous |
|||
| Epidermal-derived growth factor (EGF) |
LNCaP, DU145, PC3 |
Proliferation |
8,9,89,90 |
| Transforming growth factor (TGF)-α |
PC3 |
Proliferation |
91 |
| Insulin-like growth factor (IGF) |
LNCaP, DU145, LAPC-4, PC3 |
Proliferation |
89,92 |
| Fibroblast-derived growth factors (FGF) |
LNCaP |
Growth |
93 |
| Interluekin (IL)-6 |
LNCaP |
? |
12,94 |
| Neu differentiation factor (NDF)/Heregulin |
LNCaP |
? |
81 |
| Lysophosphatidic acid (LPA) |
DU145, PC3 |
Proliferation |
9,95 |
| Bombesin |
DU145, PC3 |
Proliferation |
22,95 |
| Bradykinin |
PC3 |
Proliferation |
96 |
| Epinephrine |
LNCaP |
NE diff (?) |
94 |
| Adenosine triphosphate |
tumor spheroids |
? |
97 |
| Vitamin D |
LNCaP |
? |
47 |
| 5-HETE |
PC3 |
Proliferation |
26 |
| 13-(S)-HODE |
PC3 |
? |
38 |
| Nitric oxide (NO) |
LNCaP, PC3 |
? |
37 |
| Androgens |
|||
| Testosterone |
LNCaP |
Survival |
50 |
| Dihydrotestosterone (DHT)* |
Primary prostate stromal, LNCaP |
? |
10 |
| Hydroxyflutamide (antiandrogen) |
DU145, PC3AR2, CWR22 |
? |
98 |
| Exogenous |
|||
| Heat |
PC3 |
? |
33 |
| Hypoxia |
LNCaP, PC3 |
? |
37 |
| ionizing radiation |
DU145 |
Survival |
53 |
| Resveratrol (stilbene) |
DU145 |
Apoptosis |
45 |
| Phenylethyl isothiocyanate (PEITC) |
PC3 |
Apoptosis |
46 |
| DDT (pesticide) |
LNCaP |
? |
99 |
|
1 *not supported by other studies. | |||
Maroni et al. Cell Communication and Signaling 2004 2:5 doi:10.1186/1478-811X-2-5 |
|||
